FDA Must Do More To Counter Misinformation On Biosimilars

 
• By Dave Wallace

More should be done by the FDA to counter misinformation perpetuated by originators over biosimilars, the AAM and its Biosimilars Council have urged in comments attached to a citizen petition lodged by Pfizer.

Megaphones
The FDA Should Stop Patients From Being Misled, The Council Insists • Source: Shutterstock

More from Regulation

More from Policy & Regulation